Production (Stage)
Avenue Therapeutics, Inc.
ATXI
$0.2088
-$0.0113-5.13%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.53% | -9.32% | -28.60% | 63.17% | 33.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.62% | -24.68% | 52.61% | -28.04% | -42.32% |
| Operating Income | 48.62% | 24.68% | -52.61% | 28.04% | 42.32% |
| Income Before Tax | 57.28% | -352.67% | -701.75% | 32.74% | 42.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 57.28% | -352.67% | -701.75% | 32.74% | 42.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -33.33% | -34.78% | -15.38% | 0.00% | -86.36% |
| Net Income | 57.33% | -341.25% | -684.79% | 32.82% | 42.41% |
| EBIT | 48.62% | 24.68% | -52.61% | 28.04% | 42.32% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 91.93% | 67.03% | -139.55% | 83.40% | 92.40% |
| Normalized Basic EPS | 91.93% | -134.54% | -138.88% | 93.79% | 92.37% |
| EPS Diluted | 95.95% | 67.03% | -139.55% | 83.40% | 84.84% |
| Normalized Diluted EPS | 91.93% | -134.54% | -138.88% | 93.79% | 92.37% |
| Average Basic Shares Outstanding | 428.61% | 579.81% | 1,378.93% | 981.04% | 657.41% |
| Average Diluted Shares Outstanding | 428.61% | 579.81% | 1,378.93% | 981.04% | 657.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |